SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and design

Reiner Jumpertz von Schwartzenberg, Norbert Stefan, Robert Wagner, Martina Guthoff, Arvid Sandforth, Andrea Icks, Matthias Blüher, Jochen Seissler, Julia Szendrödi, Michael Roden, Christoph Wanner, Hiddo J. L. Heerspink, Hubert Preissl, Andreas Fritsche, Andreas L. Birkenfeld
doi: https://doi.org/10.1101/2023.11.18.23298622

Article usage

Article usage: November 2023 to July 2025

AbstractFullPdf
Nov 2023141955
Dec 202390225
Jan 202432016
Feb 202447018
Mar 202440315
Apr 202451137
May 202426419
Jun 20243229
Jul 202425315
Aug 20241515
Sep 202430320
Oct 202427912
Nov 20242226
Dec 202415012
Jan 202537313
Feb 202516112
Mar 202550728
Apr 202570430
May 202561625
Jun 2025541721
Jul 20251006
Back to top
Posted November 18, 2023.
Download PDF
Data/Code
Email
SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and design
Reiner Jumpertz von Schwartzenberg, Norbert Stefan, Robert Wagner, Martina Guthoff, Arvid Sandforth, Andrea Icks, Matthias Blüher, Jochen Seissler, Julia Szendrödi, Michael Roden, Christoph Wanner, Hiddo J. L. Heerspink, Hubert Preissl, Andreas Fritsche, Andreas L. Birkenfeld
medRxiv 2023.11.18.23298622; doi: https://doi.org/10.1101/2023.11.18.23298622
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area